Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), David L. Grinblatt(NorthShore University HealthSystem), E. Dawn Flick, Pavel Kiselev, Thomas J. Kipps(University of California San Diego), Charles M. Farber(Morristown Medical Center), Matthew S. Davids(Dana-Farber Cancer Institute), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Arlene S. Swern, Chadi Nabhan(University of Chicago), Kristen Sullivan, Neil E. Kay(Mayo Clinic), Shriya Bhushan, Nicole Lamanna(Memorial Sloan Kettering Cancer Center)
Cited by 29
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k